Waltham, MA — BG Medicine, Inc. announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range of the offering have not yet been determined.
Jefferies & Company and UBS Investment Bank will act as the joint bookrunning managers for the offering. Cowen and Company and Thomas Weisel Partners LLC will act as co-managers for the offering.
This offering will be made only by means of a prospectus. Copies of the preliminary prospectus for this offering, when available, may be obtained by contacting: Jefferies & Company, 520 Madison Avenue, New York, NY 10022, Attention: Syndicate Prospectus Department, (888) 449-2342; and UBS Investment Bank at 299 Park Avenue, New York, NY 10171, Attention: Prospectus Department, (888)827-7275.
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About BG Medicine (www.BG-Medicine.com)
BG Medicine is a life sciences company focused on the discovery, development, and commercialization of novel diagnostics based on biomarkers to improve patient outcomes and contain healthcare costs. BG Medicine’s proprietary technology platform enables rapid and cost effective discovery of new high?value diagnostics biomarkers over a broad range of therapeutic areas.